Worah D, Berger A E, Burnett K R, Cockrill H H, Kanal E, Kendall C, Leese P T, Lyons K P, Ross E, Wolf G L
Salutar, Inc., Sunnyvale, California 94086.
Invest Radiol. 1988 Sep;23 Suppl 1:S281-5. doi: 10.1097/00004424-198809001-00061.
The preclinical and clinical trial experience with ferrioxamine (S-FDF; Salutar, Inc.) as a contrast agent for magnetic resonance imaging (MRI) is summarized. The results in 44 patients or subjects show that the drug is safe and well tolerated when given intravenously. In certain conditions, early results show that the use of this contrast agent provides more information than can be obtained with MRI alone.
总结了去铁胺（S-FDF；Salutar公司）作为磁共振成像（MRI）造影剂的临床前和临床试验经验。44例患者或受试者的结果表明，静脉给药时该药物安全且耐受性良好。在某些情况下，早期结果表明，使用这种造影剂能提供比单纯MRI更多的信息。
